To be an international destination center that develops and delivers innovative and personalized cancer therapies.
ITOR is a major pillar of translational cancer research at GHS. The efforts of ITOR include a phase I Clinical Research Unit, a Biorepository Services platform, and proteomics & genomics capabilities.
ITOR advances cancer care on multiple levels, facilitating pioneering research as well as clinical care delivery. ITOR is committed to “translational” medicine, which is a branch of medical research that forges a direct link between basic research and patient care. In the case of drug therapies, translational medicine refers to the “translation” of basic research into beneficial drug treatments for patients.
ITOR focuses on discovering and developing drugs that help people who have cancer.
- Achieve the most efficient translation of basic science into the clinical investigation of cancer care
- Discover and develop clinically meaningful molecular and genomic markers with prognostic and predictive capabilities
- Create an environment in which to educate and train medical professionals in translational and personalized medicine
While modest advances continue to be made in the prevention, diagnosis and treatment of cancers, in order to effectively and rapidly transfer basic science data and discovery into meaningful clinical benefit, it is ITOR’s belief that the existing culture of cancer research must place more value and emphasis on translational and clinical research.
As such, ITOR aspires to be one of the country’s leaders in the fulfillment of an unprecedented translational research model of the future – through its unique vision, capabilities, consortia of expert partners, and focus on diagnostic and therapeutic treatments of cancer.
An ultimate goal is to help develop breakthroughs in rapid drug development and accompanying diagnostic discovery through new cutting-edge business models and emerging technologies – including genomic profiling of cancer tumors and the design of clinical trials utilizing known targets that are expressed, versus disease specific, in order to achieve true personalized medicine – ultimately advancing cancer care for patients.
ITOR’s commitment to this proposition will be achieved in part through translational research initiatives undertaken in partnership with fellow collaborators.